Evoked Potential Studies
Customize your policy alerts
Sign up for Aetna Policy 0181 alerts
Get alerted when Policy 0181 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity, investigational exclusions, and applicable CPT/HCPCS/ICD-10 codes for various evoked potential studies (SEPs/DSEPs, VEPs, BAER/ABR, cVEMP, VEMP, otoacoustic emissions, motor evoked potentials) as applied by Aetna.
There are no material clinical or coverage changes in this update; has_material_change=false in the brief.
Coverage Summary
This policy addresses clinical coverage for a range of evoked potential modalities including somatosensory/dermatosensory evoked potentials (SEPs/SSEPs/DSEPs), visual evoked potentials (VEPs), brainstem auditory/brainstem auditory evoked response (BAER/ABR, including BAER/ABR limited and comprehensive), vestibular evoked myogenic potentials (cVEMP, oVEMP, VEMP), evoked otoacoustic emissions (OAE), and motor evoked potentials (MEP). The overall coverage stance is mixed: specific indications are listed as medically necessary, while many other uses are considered experimental/investigational or not covered. For intraoperative monitoring indications, this policy refers to the separate intraoperative neurophysiological monitoring policy CPB 0697.
Medical-Necessity Criteria
Somatosensory evoked potentials (SEPs, SSEPs) - Medically Necessary
Considered medically necessary for any of the following indications:
SEPs / DSEPs - Experimental and Investigational
Considered experimental and investigational for all other indications because effectiveness not established.
Visual Evoked Potentials (VEPs) - Medically Necessary
Considered medically necessary for any of the following indications:
VEPs - Experimental and Investigational
VEPs are considered experimental and investigational for other indications not listed above.
Brain Stem Auditory Evoked Response (BAER/ABR) - Medically Necessary
Considered medically necessary for any of the following:
BAER/ABR - Experimental and Investigational
BAERs are considered experimental and investigational for all other indications not listed above.
Cervical Vestibular Evoked Myogenic Potential (cVEMP) - Medically Necessary
Considered medically necessary when specific preconditions met:
Requires prior comprehensive evaluation
cVEMP / VEMP / oVEMP - Experimental and Investigational
Considered experimental and investigational for other specified uses:
Evoked Otoacoustic Emissions (OAE) - Medically Necessary (Screening)
Screening/OAE coverage rules:
Motor Evoked Potentials (non-intraoperative) - Not Covered / Experimental
Motor evoked potentials (other than intraoperative with SSEPs) are not covered/considered experimental for indications listed:
Codes Not Covered (motor evoked potentials)
CPT and ICD-10 codes explicitly listed as not covered for indications in the clinical policy bulletin (CPB):
CPT codes not covered for indications listed in the CPB:
ICD-10 codes not covered for indications listed in the CPB:
- E83.01 — Wilson's disease.
Codes Not Covered (VEMP)
Vestibular evoked myogenic potentials CPT/ICD-10 codes listed as not covered for indications in the CPB:
CPT codes not covered for indications listed in the CPB:
- 92517 — Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP).
- 92518 — Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP).
- 92519 — Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP).
ICD-10 codes not covered for indications listed in the CPB:
- G43.801 - G43.819 — Other migraine [vestibular migraine].
- H81.01 - H81.09 — Meniere's disease.
- H81.10 - H81.13 — Benign paroxysmal vertigo.
- H81.20 - H81.23 — Vestibular neuronitis.
Other ICD-10 codes referenced (screening exam only for members < 3 yrs.)
ICD-10 codes listed in this part as related to screening or examination contexts:
Documentation Requirements
To qualify for coverage, medical necessity criteria and documentation must be present in the medical record:
Operational billing guidance regarding baseline vs intraoperative reporting: Time spent performing or interpreting baseline electrophysiologic studies prior to surgery should not be counted as intraoperative monitoring but represents separately reportable procedures; testing performed during surgery does not qualify as baseline testing and is not a separately reportable procedure.
Coding
| 95925 | Short-latency somatosensory evoked potential study, stimulation of any/all peripheral nerves or skin sites, recording from the central nervous system; in upper limbs. |
| 95926 | in lower limbs. |
| 95927 | in the trunk or head. |
| 95938 | in upper and lower limbs. |
| G11.1 | Early-onset cerebellar ataxia [Friedreich's ataxia]. |
| G23.8 | Other specified degenerative diseases of basal ganglia [OPC degeneration]. |
| G35 | Multiple sclerosis [with clinically silent lesions]. |
| G36.0 - G37.9 | Other demyelinating diseases of central nervous system. |
| G93.1 | Anoxic brain damage, not elsewhere classified. |
| G93.82 | Brain death. |
| E53.8 | Deficiency of other specified B group vitamins [diagnosis and management of acquired metabolic disorders]. |
| F43.10 - F43.12 | Posttraumatic stress disorder. |
| E70.0 - E89.89 | Metabolic disorders [diagnosis and management of acquired metabolic disorders]. |
| F90.0 - F90.9 | Attention-deficit hyperactivity disorders. |
| G12.21 | Amyotrophic lateral sclerosis. |
| G12.8 - G12.9 | Other and unspecified muscular atrophies. |
| G25.81 - G25.89 | Other specified extrapyramidal and movement disorders. |
| G25.9 | Extrapyramidal and movement disorder, unspecified. |
| G54.0 | Brachial plexus disorders [thoracic outlet syndrome]. |
| G56.00 - G59 | Mononeuropathies of upper and lower limbs [radiculopathies, peripheral nerve lesions, carpal tunnel]. |
| 95930 | Visual evoked potential (VEP) testing central nervous system, checkerboard or flash. |
| A39.82 | Meningococcal retrobulbar neuritis. |
| A52.10 - A52.19 | Symptomatic neurosyphilis. |
| A69.20 | Lyme disease, unspecified. |
| G35 | Multiple sclerosis. |
| G36.0 - G37.9 | Other demyelinating diseases of central nervous system. |
| G93.1 | Anoxic brain damage, not elsewhere classified. |
| H47.011 - H47.9 | Disorders of the optic nerve and visual pathways. |
| H53.001 - H53.9 | Visual disturbances. |
| H81.01 - H83.2x9 | Disorders of vestibular function. |
| 0333T | Visual evoked potential, screening of visual acuity, automated [not covered for screening]. |
| 92652 | Auditory evoked potentials; for threshold estimation at multiple frequencies, with interpretation and report. |
| 92653 | Auditory evoked potentials; neurodiagnostic, with interpretation and report. |
| G93.82 | Brain death [for members >3 months of age]. |
| G93.1 | Anoxic brain damage. |
| G35 | Multiple sclerosis. |
| H83.3 - H94.83 | Other disorders of ear and hearing loss. |
| Z01.110 | Encounter for hearing examination following failed hearing screening. |
| Z79.2 | Long-term (current) use of antibiotics [damage due to ototoxic drugs]. |
| 92517 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP). |
| 92518 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP). |
| 92519 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP). |
| E83.01 | Wilson's disease. |
| G43.801 - G43.819 | Other migraine [vestibular migraine]. |
| H81.01 - H81.09 | Meniere's disease. |
| H81.10 - H81.13 | Benign paroxysmal vertigo. |
| H81.20 - H81.23 | Vestibular neuronitis |
| F80.0 - F80.9 | Specific developmental disorders of speech and language. |
| R94.120 - R94.128 | Abnormal results of function studies of ear and other special senses. |
| Z01.110 | Encounter for hearing examination following failed hearing screening. |
| Z01.118 | Encounter for examination of ears and hearing with other abnormal findings. |
| Z00.121 - Z00.129 | Encounter for routine child health examination with/without abnormal findings. |
Provider Actions & Billing Guidance
SEPs/DSEPs indication documentation
Document the indication when ordering and in the medical record. For somatosensory evoked potentials (SEPs) / dermatosensory evoked potentials (DSEPs) include the clinical rationale that meets policy-listed indications (e.g., unconscious spinal cord injury with structural somatosensory damage being considered for emergent surgery, acute anoxic encephalopathy within 3 days, suspected brain death, workup for multiple sclerosis, localization of CNS deficit unexplained by CT/MRI, spinocerebellar degeneration, unexplained myelopathy, or intraoperative monitoring per CPB 0697).
cVEMP pre-evaluation requirement
Prior to performing cervical VEMP (cVEMP), document that the patient has undergone a comprehensive vestibular evaluation (history, physical exam, audiometry, electronystagmography or videonystagmography, electrocochleography, brainstem audiometry) and that results remain inconclusive for semicircular canal dehiscence syndrome (SCDS).
OAE neonatal screening workflow
For neonatal screening workflows, routine limited otoacoustic emissions (OAE) or limited auditory evoked potentials are the appropriate screening tests. Document screening context (neonatal screen, fail/pass result) and follow-up plan. Comprehensive OAE or comprehensive auditory evoked response testing should only be used after failed screening per policy.
Use appropriate ICD-10 codes for screening context
When ordering/claiming tests performed in a screening context, ensure the medical record and claim use the appropriate ICD-10 diagnosis codes that justify screening rather than diagnostic evaluation (e.g., newborn screening scenario or specific neonatal hearing screen failure).
- Use applicable ICD-10 screening/failure codes as documented in the patient's record
Do not bill excluded CPT codes for CPB-listed indications
Do not bill the listed CPT codes when the service is excluded by the CPB indications (i.e., when policy labels the use as not medically necessary or experimental for the specific indication). Providers should verify the clinical indication meets policy criteria before billing these CPT codes.
VEMP as part of diagnostic battery for Meniere disease
Use vestibular evoked myogenic potentials (VEMP) as part of a diagnostic battery when evaluating Meniere disease; document that VEMP was performed as one component of a comprehensive vestibular assessment. Note that policy considers broader use of VEMP experimental/investigational for several vestibular indications, so document the specific clinical question and how VEMP results influenced management.
- Use VEMP as part of diagnostic battery for Meniere disease
oVEMP/RoVEMP utility
Ocular VEMP (oVEMP) and rostral oVEMP (RoVEMP) may provide supportive information in select cases and can aid in the evaluation of myasthenia gravis (MG) in conjunction with other diagnostic testing. Document the specific diagnostic role and how results contributed to diagnosis or management decisions.
- oVEMP/RoVEMP may aid MG diagnosis
cVEMP abnormality predictive note
Report and document any abnormal cVEMP findings and note that certain cVEMP abnormalities have been reported to predict conversion to Meniere disease in longitudinal studies; include how this information affected monitoring or treatment planning.
- cVEMP abnormalities may predict conversion to Meniere disease
Medical record documentation for coverage
Maintain thorough medical record documentation to support coverage: clinical history, indication for the test, prior diagnostic workup and results, rationale for selecting the specific evoked potential study, test report with interpretation, and how the test result informed patient management. Lack of adequate documentation may result in claim denial.
- Medical record must contain history, prior testing, rationale, report, and management impact
BAER-specific documentation
For BAER/ABR testing, document the specific indication consistent with policy (e.g., suspected brain death assessment, intraoperative monitoring per CPB 0697, suspected acoustic neuroma, infants/children under 3 with suspected hearing loss or those who failed screening). Include test parameters, whether limited or comprehensive testing was performed, and referral/follow-up actions.
- BAER-specific documentation: indication, parameters, limited vs comprehensive, follow-up plan
Baseline testing reporting
Baseline (screening) evoked potential tests that are reported as part of a screening program should be billed and reported consistent with policy: limited screening codes only for neonatal/infant screening where indicated, and comprehensive testing only when medically necessary and documented. Do not bill baseline/screening using comprehensive CPT codes when policy restricts screening to limited tests.
- Baseline testing reporting — use limited screening codes for neonatal screening; comprehensive tests require documented medical necessity
Interpretation caution for cooled neonates
Exercise caution when interpreting BAER/evoked potential results in cooled neonates; document the clinical context (therapeutic hypothermia) and note potential effects of cooling on test results.
- Interpretation caution for cooled neonates
VEMP as part of battery
When VEMP is performed, consider and document it as part of a multi-test vestibular battery rather than a standalone definitive test; this supports appropriate clinical use and aligns with policy which limits certain VEMP indications.
- VEMP should be documented as part of a diagnostic battery
Evidence, Definitions, and Notes
The Evidence section summarizes systematic reviews, diagnostic accuracy studies, cohort and case-control studies, and guideline statements that inform the policy's recommendations; a full reference list is provided (references 81–145) to support the evidence summaries and conclusions.
| Study / Measure | Result / Value |
|---|---|
| Van Laerhoven et al (2013) pooled VEP performance | |
| VEPs sensitivity 0.90 (0.74-0.97); specificity 0.92 (0.68-0.98) | |
| UpToDate / Wijdicks et al (SSEP prognostic) - post-cardiac arrest | |
| Bilateral absence of N20 within 1-3 days predicts poor outcome with pooled LR 12.0 and false-positive rate 0% | |
| Garfinkle et al (2015) - neonatal SEPs after hypothermia | |
| Bilateral absent N19 PPV 0.36; NPV 0.93 (shows lower PPV with therapeutic hypothermia) | |
| Silverstein et al (2014) - saphenous nerve SSEP intraoperative series | |
| Changes in SSEP in 5 of 41 procedures; 3 patients woke with femoral nerve deficit; none with stable SSEP developed deficits | |
| Fix et al (2015) - FVEP-P2 in MCI/AD | |
| Double-flash 100 ms condition showed higher predictive accuracy vs single-flash for FVEP-P2 latency | |
| Valko et al (2016) - oVEMP for myasthenia gravis | |
| oVEMP sensitivity 89%, specificity 64% (unilateral decrement >=15.2%) | |
| De Meel et al (2020) - RoVEMP for MG | |
| RoVEMP cut-off >=14.3%: sensitivity 67%, specificity 82%; mean decrement 28.4% ± 32.2 in MG patients | |
| Egami et al (2013) - VEMP for Meniere's disease | |
| VEMP sensitivity 50.0%, specificity 48.9%; combined VEMP+caloric sensitivity 65.8% | |
| Xu et al (2019) - ECochG/cVEMP diagnostic accuracy | |
| ECochG diagnostic accuracy 74% (sensitivity 65%, specificity 78%); cVEMP accuracy 67% (sensitivity 62%, specificity 68%) | |
| Bembenek et al (2015) - MEPs in Wilson's disease | |
| Abnormal MEPs reported in 20-70% across small heterogeneous studies |
The document scope covers clinical use and coverage criteria for evoked potential studies across diagnostic and screening contexts and distinguishes intraoperative monitoring (see CPB 0697) from non‑intraoperative testing. It also differentiates limited vs comprehensive auditory testing for neonatal screening: limited ABR or limited OAE are appropriate for newborn/infant screening, with referral for comprehensive testing only if screening is failed or if indicated (neonates/children < 3 years).
| Term | Definition |
|---|---|
| BAER | |
| Also known as auditory brainstem response (ABR), auditory evoked potentials (AEPs), brainstem auditory evoked potentials (BAEP), BERA, BSER, BSRA. | |
| cVEMP | |
| Cervical vestibular evoked myogenic potential. | |
| SSEP / SEP | |
| Somatosensory evoked potentials that assess conduction in somatosensory pathways. | |
| VEP / VER | |
| Visual evoked potentials/responses measuring visual pathway function using flashes or pattern reversal stimuli. | |
| VEMP | |
| Vestibular evoked myogenic potentials assessing saccular/vestibular function recorded from neck/ocular muscles. | |
| oVEMP | |
| Ocular vestibular evoked myogenic potential, assesses extra-ocular muscle responses to vibration or sound stimuli. | |
| RoVEMP | |
| Repetitive ocular vestibular evoked myogenic potential, a repetitive-stimulation variant used in myasthenia gravis evaluation. | |
| MEP | |
| Monitors motor pathways; transcranial electrical stimulation elicits excitation of corticospinal projections. | |
| SSEP | |
| Monitors the dorsal column–medial lemniscus pathway; stimulation of peripheral sensory receptors initiates peripheral sensory nerves through the nerve root to dorsal root ganglia. |
Medicare Determinations
| Name | Number | Type | Effective Date |
|---|---|---|---|
| Novitas Solutions L32640 - Neurophysiology Evoked Potentials (NEPs) | |||
| L32640 | |||
| LCD | |||
| 2012-11-19 |
Revision History
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.